Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Proc Natl Acad Sci U S A. 1993 May 15; 90(10): 4419–4420.
doi: 10.1073/pnas.90.10.4419
PMCID: PMC46522
PMID: 8506281

A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

H M Temin
Author information Copyright and License information PMC Disclaimer

Abstract

Human immunodeficiency virus type 1 (HIV-1) is a more complex retrovirus, coding for several accessory proteins in addition to the structural proteins (Gag, Pol, and Env) that are found in all retroviruses. More complex retroviruses have not been isolated from birds, and simpler retroviruses have not been isolated from humans. However, the proviruses of many endogenous simpler retroviruses are present in the human genome. These observations suggest that humans can mount a successful protective response against simpler retroviruses, whereas birds cannot. Thus, humans might be able to mount a successful protective response to infection with a simpler HIV-1. As a model, a simpler bovine leukemia virus which is capable of replicating has been constructed; a simpler HIV-1 could be constructed in a similar fashion. I suggest that such a simpler HIV-1 would be a safe and effective vaccine against HIV-1.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (467K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

 
icon of scanned page 4419
4419
icon of scanned page 4420
4420
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Sabin AB. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8852–8855. [PMC free article] [PubMed] [Google Scholar]
  • Hilleman MR. The dilemma of AIDS vaccine and therapy. Possible clues from comparative pathogenesis with measles. AIDS Res Hum Retroviruses. 1992 Oct;8(10):1743–1747. [PubMed] [Google Scholar]
  • Ada G, Blanden B, Mullbacher A. HIV: to vaccinate or not to vaccinate? Nature. 1992 Oct 15;359(6396):572–572. [PubMed] [Google Scholar]
  • Desrosiers RC. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses. 1992 Mar;8(3):411–421. [PubMed] [Google Scholar]
  • Vaishnav YN, Wong-Staal F. The biochemistry of AIDS. Annu Rev Biochem. 1991;60:577–630. [PubMed] [Google Scholar]
  • Larsson E, Kato N, Cohen M. Human endogenous proviruses. Curr Top Microbiol Immunol. 1989;148:115–132. [PubMed] [Google Scholar]
  • Leib-Mösch C, Brack-Werner R, Werner T, Bachmann M, Faff O, Erfle V, Hehlmann R. Endogenous retroviral elements in human DNA. Cancer Res. 1990 Sep 1;50(17 Suppl):5636S–5642S. [PubMed] [Google Scholar]
  • Harada F, Tsukada N, Kato N. Isolation of three kinds of human endogenous retrovirus-like sequences using tRNA(Pro) as a probe. Nucleic Acids Res. 1987 Nov 25;15(22):9153–9162. [PMC free article] [PubMed] [Google Scholar]
  • Mager DL, Freeman JD. Human endogenous retroviruslike genome with type C pol sequences and gag sequences related to human T-cell lymphotropic viruses. J Virol. 1987 Dec;61(12):4060–4066. [PMC free article] [PubMed] [Google Scholar]
  • Ono M, Kawakami M, Takezawa T. A novel human nonviral retroposon derived from an endogenous retrovirus. Nucleic Acids Res. 1987 Nov 11;15(21):8725–8737. [PMC free article] [PubMed] [Google Scholar]
  • Mariani-Costantini R, Horn TM, Callahan R. Ancestry of a human endogenous retrovirus family. J Virol. 1989 Nov;63(11):4982–4985. [PMC free article] [PubMed] [Google Scholar]
  • Callahan R, Chiu IM, Wong JF, Tronick SR, Roe BA, Aaronson SA, Schlom J. A new class of endogenous human retroviral genomes. Science. 1985 Jun 7;228(4704):1208–1211. [PubMed] [Google Scholar]
  • Repaske R, Steele PE, O'Neill RR, Rabson AB, Martin MA. Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol. 1985 Jun;54(3):764–772. [PMC free article] [PubMed] [Google Scholar]
  • O'Connell C, O'Brien S, Nash WG, Cohen M. ERV3, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships. Virology. 1984 Oct 30;138(2):225–235. [PubMed] [Google Scholar]
  • Welsh RM, Jr, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumour viruses. Nature. 1975 Oct 16;257(5527):612–614. [PubMed] [Google Scholar]
  • Karacostas V, Nagashima K, Gonda MA, Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8964–8967. [PMC free article] [PubMed] [Google Scholar]
  • Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol. 1990 Jun;64(6):2653–2659. [PMC free article] [PubMed] [Google Scholar]
  • Vzorov AN, Bukrinsky MI, Grigoriev VB, Tentsov YYu, Bukrinskaya AG. Highly immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus-infected cells. AIDS Res Hum Retroviruses. 1991 Jan;7(1):29–36. [PubMed] [Google Scholar]
  • Hoshikawa N, Kojima A, Yasuda A, Takayashiki E, Masuko S, Chiba J, Sata T, Kurata T. Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study. J Gen Virol. 1991 Oct;72(Pt 10):2509–2517. [PubMed] [Google Scholar]
  • Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, Bahraoui E. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol. 1991 Feb;65(2):961–967. [PMC free article] [PubMed] [Google Scholar]
  • Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science. 1991 Nov 15;254(5034):963–969. [PubMed] [Google Scholar]
  • Peters G. Oncogenes at viral integration sites. Cell Growth Differ. 1990 Oct;1(10):503–510. [PubMed] [Google Scholar]
  • Moolten FL, Cupples LA. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum Gene Ther. 1992 Oct;3(5):479–486. [PubMed] [Google Scholar]
  • Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol. 1992 Dec;66(12):7176–7182. [PMC free article] [PubMed] [Google Scholar]
  • Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. [PubMed] [Google Scholar]
  • Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990 Feb 21;82(4):297–300. [PubMed] [Google Scholar]
  • Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33–37. [PMC free article] [PubMed] [Google Scholar]
  • Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol. 1991 Dec;11(12):5848–5859. [PMC free article] [PubMed] [Google Scholar]
Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences
-